What is the estimated monthly volume of Toujeo (insulin glargine) needed for a patient taking 80 units daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Monthly Volume Calculation for Toujeo 80 Units Daily

For a patient taking 80 units of Toujeo (insulin glargine U-300) daily, approximately 8 mL per month is required.

Volume Calculation

  • Toujeo is a concentrated formulation containing 300 units per mL (U-300), compared to standard insulin glargine which contains 100 units per mL 1
  • At 80 units daily: 80 units ÷ 300 units/mL = 0.267 mL per day
  • Monthly volume: 0.267 mL/day × 30 days = approximately 8 mL per month

Practical Dispensing Considerations

  • Toujeo is typically available in 1.5 mL prefilled pens (SoloStar) or 3 mL pens (Max SoloStar), containing 450 units and 900 units respectively 1
  • For 80 units daily (2,400 units/month), the patient would require:
    • Approximately 3 SoloStar pens (1.5 mL each) per month, or
    • Approximately 3 Max SoloStar pens (3 mL each) per month

Important Clinical Context for This Dose

This 80-unit daily dose warrants clinical review. When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, adding prandial insulin or GLP-1 receptor agonist therapy is more appropriate than continuing to escalate basal insulin alone 1, 2. Clinical signals suggesting overbasalization include basal doses >0.5 units/kg, high bedtime-to-morning glucose differential (≥50 mg/dL), hypoglycemia, and high glucose variability 1.

U-300 vs U-100 Dosing Caveat

  • U-300 glargine (Toujeo) requires approximately 10-18% higher daily doses compared to U-100 glargine (Lantus) to achieve equivalent glycemic control 1
  • The concentrated formulation allows higher doses per volume but has modestly lower efficacy per unit 1
  • Patients should not be switched between U-100 and U-300 formulations on a unit-per-unit basis without dose adjustment and close monitoring 1

References

Guideline

Insulin Glargine Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.